factor XI inhibitor

Ph. II candidate for CV (fibrillation, stroke, MI)

related to previous series

Br. J. Clin. Pharmacol.

Bayer AG

factor XI inhibitor - Bayer AG

asundexian (BAY2433334) is a reversible Factor XIa active site inhibitor previously disclosed at the 2021 EFMC-ISMC conference. This article highlights the Ph. I data of asundexian in healthy volunteers,…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: